Anju Majeed, Ph.D., and Shaheen Majeed Step into Executive Roles at Sami-Sabinsa Group

From L: Anju Majeed, Ph.D., and Shaheen Majeed
From L: Anju Majeed, Ph.D., and Shaheen Majeed
Sabinsa Corp.

Sami-Sabinsa Group, founded by the late Muhammed Majeed, Ph.D., 36 years ago, has named Anju Majeed, Ph.D., executive chairperson, assuming the role her late father, and Shaheen Majeed as global managing director and CEO.

See related: In Memory of Sami-Sabinsa Group's Founder: Muhammed Majeed, Ph.D.

A. Majeed earned her bachelor's and master's degree from Rutgers University in microbiology and molecular genetics, an additional master's in biological sciences from Johns Hopkins, and doctorate in microbiology from Bharathidasan University. She was a National Institute of Health Research Fellow from 2001–2005 and she has expertise in SAS and clinical SAS database management.

Based at the Sami-Sabinsa Group headquarters in Bengaluru, India, A. Majeed has driven new technologies and processes, developed new product formulations and created scalable manufacturing processes for Sami, which are further used in clinical trials through all phases of development. As Sami-Sabinsa Group director and senior scientist, she has worked closely with analytical and formulation scientists and operated via multifunctional global teams, including API manufacturing, process R&D, pre-formulation, and pilot plant operations.

S. Majeed has been inducted onto the board of directors for the Sami-Sabinsa Group, effective April 1, 2024, and will head the Sami-Sabinsa Group as global managing director and chief executive officer. For 25 years, S. Majeed played a key role in building Sabinsa into a global leader with a vast ingredient portfolio. He has held various positions of increasing responsibilities, including roles in sales, supply chain, manufacturing and global marketing, culminating in four years as president, worldwide.

He was instrumental in executing the global strategies, expanding the company's footprints, ensuring cGMP and regulatory compliance and guiding several clinical studies through the publishing process. He currently holds 46 US. and international patents, and previously served as CEO of three subsidiaries of BGG World: HB Natural Ingredients, BGG Americas and Algae Health Sciences.

More in News